Assembly Biosciences (ASMB) Stock Price, News & Analysis

Company Overview

Assembly Biosciences, Inc. (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle. Vebicorvir (ABI-H0731), a next-generation CpAM, is being studied in combination regimens to assess its ability to reduce surface antigen levels and achieve durable viral control. Assembly is also advancing ABI-H2158, an oral antiviral with broad potential to enhance host immune response and further suppress viral replication in chronic HBV patients.

Assembly conducts multi-center clinical trials across North America, Europe and Asia, collaborating with academic centers and global research networks to evaluate its candidates in diverse patient populations. The company operates its headquarters in Boulder, Colorado, with additional research activities in Cambridge, Massachusetts. Its management team brings extensive experience in antiviral drug development, leveraging prior success in hepatitis and oncology therapeutic programs.

Since its inception in 2015, Assembly has grown through strategic partnerships and in-licensing agreements, establishing a robust intellectual property portfolio around core modulation and prenylation inhibition. The company continues to engage regulatory authorities worldwide with the goal of delivering new, safe and effective treatment options for patients living with chronic HBV and HDV infections.

Key Stats

• Today's Range: $26.36 to $27.12
• 50-Day Range: $22.26 to $28.97
• 52-Week Range: $20.23 to $39.71
• Volume: 119,772 shs
• Average Volume: 139,760 shs
• Market Capitalization: $423.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Moderate Buy

Assembly Biosciences Stock Analysis - MarketRank™

Assembly Biosciences scored higher than 32% of companies evaluated by MarketBeat, and ranked 739th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Assembly Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Assembly Biosciences has a consensus price target of $44.00, representing about 64.9% upside from its current price of $26.68.

Amount of Analyst Coverage

Assembly Biosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Assembly Biosciences are expected to decrease in the coming year, from $1.90 to ($0.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Assembly Biosciences is -242.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Assembly Biosciences is -242.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Assembly Biosciences has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.08% of the float of Assembly Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Assembly Biosciences has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Assembly Biosciences has recently decreased by 3.98%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Assembly Biosciences does not currently pay a dividend.

Dividend Growth

Assembly Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Assembly Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $674.00 in company stock.

Percentage Held by Insiders

3.50% of the stock of Assembly Biosciences is held by insiders.

Percentage Held by Institutions

19.92% of the stock of Assembly Biosciences is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 8/09/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ASMB
• CIK: 1426800
• Web: www.assemblybio.com
• Phone: (833) 509-4583
• Fax: 646-706-5101
• Employees: 100
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Assembly Biosciences: $44.00
• High Price Target: $50.00
• Low Price Target: $38.00
• Potential Upside/Downside: +64.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 14.04
• P/E Growth: N/A
• Net Income: -$6.12 million
• Net Margins: -8.98%
• Pretax Margin: -8.98%
• Return on Equity: -4.21%
• Return on Assets: -3.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.65
• Quick Ratio: 6.65

Sales & Book Value

• Annual Sales: $72.30 million
• Price / Sales: 5.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.04 per share
• Price / Book: 2.05

Miscellaneous

• Outstanding Shares: 15,890,000
• Free Float: 15,337,000
• Market Cap: $423.95 million
• Optionable: Optionable
• Beta: 1.10